natgillin/translations-raw huggingface dataset:
No overall differences in safety or effectiveness were observed between these older patients and younger patients.
V splošnem ni bilo opaziti razlik glede varnosti in učinkovitosti med skupino starejših in mlajših bolnikov
No overall differences in safety or effectiveness were observed between these patients and younger patients therefore there is no need for dose adjustment in elderly patients.
Med temi in mlajšimi bolniki niso opazili splošnih razlik v varnosti ali učinkovitosti, zato pri starejših bolnikih ni potrebno prilagajati odmerka.
No overall differences in safety or effectiveness were observed between women aged >65 years and younger women, but greater sensitivity of some older individuals cannot be ruled out.
Med ženskami, starimi > 65 let in mlajšimi, na splošno niso opazili razlik v varnosti ali učinkovitosti, vendar večje občutljivosti nekaterih starejših žensk ni mogoče izključiti.
No overall differences in safety or efficacy were observed between these patients and younger patients
V celoti med temi bolniki in mlajšimi bolniki niso ugotovili razlik v varnosti in učinkovitosti.
No overall differences in safety or efficacy were reported between elderly ( ≥65 years) and younger patients (< 65 years).
O posebnih razlikah v varnosti in učinkovitosti med starostniki (≥ 65 let) in mlajšimi bolniki (< 65 let) niso poročali.
No overall differences in safety or efficacy were reported between elderly patients (≥ 65 years) and younger patients (< 65 years).
Na splošno niso ugotovili razlik v varnosti in učinkovitosti med starejšimi (≥ 65 let) in mlajšimi bolniki (< 65 let).
No overdoses with DepoCyte have been reported.
O prevelikem odmerjanju zdravila DepoCyte ne poročajo.
No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Corbilta therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2).
Študije, v katerih bi posebej preučevali farmakokinetiko levodope in karbidope pri bolnikih z ledvično insuficienco niso bile izvedene, zato je potrebna previdnost pri dajanju zdravila Corbilta bolnikom s hudo prizadetostjo ledvic kot tudi tistim, ki se zdravijo z dializo (glejte poglavje 5.2.).
No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Levodopa/Carbidopa/Entacapone Orion therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2).
Študije, v katerih bi posebej preučevali farmakokinetiko levodope in karbidope pri bolnikih z ledvično insuficienco niso bile izvedene, zato je potrebna previdnost pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom s hudo prizadetostjo ledvic kot tudi tistim, ki se zdravijo z dializo (glejte poglavje 5.2.).
No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Stalevo therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2).
Študije, v katerih bi posebej preučevali farmakokinetiko levodope in karbidope pri bolnikih z ledvično insuficienco niso bile izvedene, zato je potrebna previdnost pri dajanju zdravila Stalevo bolnikom s hudo prizadetostjo ledvic kot tudi tistim, ki se zdravijo z dializo (glejte poglavje 5.2.).
No patient developed grade4 thrombocytopenia.
Pri nobenem bolniku se ni razvila trombocitopenija 4. stopnje.
No patient developed HAHA to Gazyvaro during or following Gazyvaro treatment.
Pri nobenem bolniku se niso razvila HAHA na zdravilo Gazyvaro po zdravljenju z zdravilom Gazyvaro.
No patient experienced HBV re-infection.
Noben bolnik se ni ponovno okužil s HBV.
No patient had a QTcF >480 msec.
Interval QTcF pri nobenem od bolnikov ni bil daljši od 480 milisekund.
No patient had a QTcF value >500 ms.
Interval QTcF pri nobenem od bolnikov ni bil daljši od 500 ms.
No patient had an absolute QTcF >500 msec while on the study medicinal product.
Absolutno trajanje intervala QTcF v času jemanja študijskega zdravila pri nobenem od bolnikov ni bilo daljše od 500 milisekund.
No patient required new dialysis with Soliris.
Noben bolnik, ki je prejemal zdravilo Soliris, ni potreboval dialize na novo.
No patients discontinued from the study due to a TEAE in the SBR arm.
V kraku z ohranitvijo začetnega režima se noben bolnik ni prenehal zdraviti zaradi neželenih učinkov, ki so se pojavili med zdravljenjem.
No patients discontinued rilpivirine due to adverse reactions.
Noben bolnik zdravljenja ni prekinil zaradi neželenih učinkov.
No patients discontinued study drug because of ADRs during the blinded study treatment phase.
Noben bolnik ni prenehal z jemanjem preskušanega zdravila zaradi pojava neželenih učinkov v fazi študije s slepim načinom zdravljenja.
No patients discontinued study drug due to ADRs.
Noben bolnik ni prenehal z jemanjem preskušanega zdravila zaradi pojava neželenih učinkov.
No patients in either group progressed to cirrhosis.
V obeh skupinah ni bilo progresije v cirozo pri nobenem bolniku.
No patients in the group treated with Perjeta plus trastuzumab and FEC followed by Perjeta plus trastuzumab and docetaxel experienced symptomatic LVD.
Pri nobenem bolniku iz skupine, zdravljene z zdravilom Perjeta, trastuzumabom in shemo FEC, ki mu je sledilo zdravljenje z zdravilom Perjeta, trastuzumabom in docetakselom, ni prišlo do pojava simptomatskega LVD.
No patients of ≥ 65 years of age were included in clinical trials.
Bolniki ≥ 65 let v klinična preskušanja niso bili vključeni.
No patients with genotype 1 HCV had on-treatment virologic failure.
Virološkega neuspeha med zdravljenjem ni doživel noben bolnik z okužbo s HCV genotipa 1.
No patients with genotype 2, 4, 5, or 6 HCV infection experienced virologic failure.
Virološkega neuspeha ni doživel noben bolnik z okužbo s HCV genotipa 2, 4, 5 ali 6.
No patients with genotype 5 HCV infection were enrolled.
Vključenih ni bilo nobenih bolnikov z okužbo s HCV genotipa 5.
No patients with organ transplant have been included in these studies (see section 4.2).
Bolniki s presajenimi organi niso bili vključeni v študiji (glejte poglavje 4.2).
No pharmacodynamic interactions have been observed.
Farmakodinamičnih interakcij niso opazili.
No pharmacokinetic (PK) interactions were observed between pertuzumab and trastuzumab, or between pertuzumab and docetaxel in a sub-study of 37 patients in the randomised, pivotal trial CLEOPATRA in metastatic breast cancer.
Pri 37 bolnikih, ki so bili vključeni v podštudijo ključnega randomiziranega preskušanja CLEOPATRA pri metastatskem raku dojk, niso opazili medsebojnega farmakokinetičnega delovanja med pertuzumabom in trastuzumabom in tudi ne med pertuzumabom in docetakselom.
No pharmacokinetic data are available for paediatric patients following hepatic transplants.
Za otroke in mladostnike z jetrnim presadkom podatkov o farmakokinetiki ni na voljo.
No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh C) (see sections 4.2 and 4.4).
Farmakokinetičnih podatkov za bolnike s hudo cirozo jeter (Child-Pugh C) ni (glejte poglavji 4.2 in 4.4).
No pharmacokinetic data are available in children or adolescents.
Pri otrocih ali mladostnikih ni na voljo nobenih farmakokinetičnih podatkov.
No pharmacokinetic data are available in paediatric patients.
Farmakokinetičnih podatkov za pediatrične bolnike ni.
No pharmacokinetic data are available in patients over 65 years of age.
Za bolnike, starejše od 65 let, podatki o farmakokinetiki niso na voljo.
No pharmacokinetic data are available in patients with haemophilia A younger than 12 years.
Farmakokinetični podatki pri bolnikih s hemofilijo A mlajših od 12 let, niso na voljo.
No pharmacokinetic data are available in patients with haemophilia A younger than 12 years.
Farmakokinetični podatki pri bolnikih s hemofilijo A, mlajših od 12 let, niso na voljo.
No pharmacokinetic data are available in patients with impaired renal or hepatic function.
Ni znano, ali se ustekinumab izloča v materino mleko pri človeku.
No pharmacokinetic data are available in patients with severe hepatic impairment.
Farmakokinetični podatki pri bolnikih s hudo okvaro jeter niso na voljo.
No pharmacokinetic data are available in the paediatric population.
Farmakokinetičnih podatkov za pediatrično populacijo ni.
No pharmacokinetic data are available in the paediatric population.
Za pediatrično populacijo ni na voljo podatkov o farmakokinetiki.
No pharmacokinetic data are currently available in patients over 65 years of age.
Za bolnike nad 65. letom starosti trenutno nimamo farmakokinetičnih podatkov.
No pharmacokinetic data exist for the Zalviso in paediatric patients.
Farmakokinetičnih podatkov za zdravilo Zalviso pri pediatričnih bolnikih ni.
No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency.
Farmakokinetičnih podatkov o zoledronski kislini pri bolnikih s hiperkalciemijo ali z insuficienco jeter ni.
No pharmacokinetic data in elderly patients are available.
Farmakokinetičnih podatkov za starejše bolnike ni na voljo.
No pharmacokinetic differences based on ethnic group were observed.
Opazili niso nikakršnih farmakokinetičnih razlik med pripadnicami različnih etničnih skupin.
No pharmacokinetic differences were observed between Japanese and Caucasian healthy volunteers.
Razlik v farmakokinetiki med zdravimi japonskimi in belskimi prostovoljci niso opazili.
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers.
V študiji pri zdravih prostovoljcih farmakokinetičnih interakcij med rivastigminom in digoksinom, varfarinom, diazepamom ali fluoksetinom niso opazili.
No pharmacokinetic or pharmacodynamic interactions were observed between liraglutide and Levemir when administering a single dose of Levemir 0.5 U/kg with liraglutide 1.8 mg at steady state in patients with type 2 diabetes.
Med liraglutidom in zdravilom Levemir niso opazili medsebojnih farmakokinetičnih ali farmakodinamskih interakcij, če je bilo zdravilo Levemir pri osebah s sladkorno boleznijo tipa 2 uporabljeno v enkratnem odmerku 0,5 e./kg z 1,8 mg liraglutida v stanju dinamičnega ravnovesja.
No pharmacokinetic studies were performed with IMBRUVICA in patients under 18 years of age.
Pri bolnikih, ki so stari manj kot 18 let, niso izvedli nobene farmakokinetične študije z zdravilom IMBRUVICA.
No pharmacokinetics study of prolonged-release exenatide has been conducted in the paediatric population.
Na pediatrični populaciji niso izvedli nobenih farmakokinetičnih študij z eksenatidom v obliki s podaljšanim sproščanjem.
No pharmacological activity has been shown for the conjugate.
Konjugat je farmakološko neaktiven.
No physical biochemical compatibility studies have been conducted to evaluate the co-administration of SYLVANT with other medicinal products.
Fizikalno-biokemijskih študij kompatibilnosti za oceno odmerjanja zdravila SYLVANT skupaj z drugimi zdravili niso opravili.
No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of ORENCIA with other agents.
Študije fizikalne in biokemične stabilnosti pri sočasni aplikaciji zdravila ORENCIA in drugih zdravil niso bile izvedene.
No PK/clinical data are available in patients with a refractory or relapsing disease.
Pri bolnikih, pri katerih se je bolezen ponovila oziroma se na prejšnje zdravljenje niso odzvali, farmakokinetičnih/kliničnih podatkov ni na voljo.
No post-marketing surveillance data are available following Adjupanrix administration.
Podatki o spremljanju cepiva Adjupanrix po pridobitvi dovoljenja za promet niso na voljo.
No post-marketing surveillance data are available following Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg administration.
Podatki o spremljanju cepiva Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals 3,75 µg po pridobitvi dovoljenja za promet niso na voljo.
No post-marketing surveillance data are available following Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics administration.
Podatkov iz spremljanja v obdobju trţenja za cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics ni.
No preceding hormonal contraceptive use (in the past month)
Če ženska pred tem ni uporabljala hormonskega kontraceptiva (v preteklem mesecu)
No preclinical safety testing with the vaccine has been conducted.
S tem cepivom niso opravili nikakršnih predkliničnih študij varnosti.
No prenatal and postnatal reproductive studies have been conducted in animals.
Študije vpliva na sposobnost razmnoževanja v prenatalnem in postnatalnem obdobja pri živalih niso bile izvedene.
No primary IN mutation1
Ni primarne mutacije IN1
No profound binding to plasma proteins, except circulating insulin antibodies (if present) has been observed.
Ugotovili niso nobene izrazite vezave na beljakovine v plazmi, razen na krožeca protitelesa proti insulinu (ce so prisotna).
No prospective efficacy trials have been performed.
Opravljeni niso bili nobeni preizkusi predvidene učinkovitosti.
No proven antidotes have been established for mitotane overdose.
Dokazanih antidotov v primeru prevelikega odmerjanja mitotana ni.
No psychiatric comorbidities
Brez sočasnega psihiatričnega obolenja
No pulmonary embolism was reported for patients with pNET who received sunitinib in the phase 3 study.
Pri bolnikih s pNET, ki so v študiji 3. faze prejemali sunitinib, niso poročali o pljučni emboliji.
No reactivity or membranous reactivity in < 10 % of tumour cells
Obarvanje ni prisotno ali pa je prisotno pri manj kot 10 % tumorskih celic.
No rebound was observed.
Niso opazili nikakršnega povratnega učinka.
No recommendation on posology can be made for children under 12.
Priporočil o odmerjanju pri otrocih, mlajših od 12 let, ni mogoče dati.
No recommendations can currently be made regarding adjustment of amprenavir dose when amprenavir is co-administered with methadone due to the inherent low reliability of non- matched historical controls.
Zaradi svojstvene nizke zanesljivosti neenakovredne kontrolne historične skupine trenutno ne moremo podati priporočil glede prilagoditve odmerka amprenavirja, če se uporablja sočasno z metadonom.
No recommendations can currently be made regarding adjustment of amprenavir dose when amprenavir is co-administered with methadone.
Priporočil glede prilagajanja odmerka amprenavirja, če se le-ta uporablja sočasno z metadonom, trenutno ne moremo podati.
No recommendations on posology can be made in this population.
Pri tej populaciji priporočil za odmerjanje ne moremo podati.
No reconstitution required
Rekonstitucija ni potrebna.
No relevant effect of gender was identified.
Pomembnega učinka spola na farmakokinetiko niso ugotovili.
No relevant effects were seen on the QTc interval, with doses of dolutegravir exceeding the clinical dose by approximately 3 fold.
Pri odmerkih, ki presegajo klinični odmerek dolutegravirja za približno 3-krat, ni bilo opaziti pomembnih vplivov na interval QTc.
No relevant inhibition by telaprevir of the organic cation transporter (OCT) OCT2 was observed in vitro.
In vitro študije niso pokazale pomembnega zaviranja organskega kationskega prenašalca OCT2 (OCT organic cation transporter) s telaprevirjem.
No reproduction toxicity or carcinogenicity studies were performed due to testing being inappropriate as the intended clinical use of Beromun is in ILP for soft tissue sarcoma treatment.
Raziskav o vplivu na razmnoževanje ali o kancerogenosti niso izvajali, ker je testiranje neustrezno glede na to, da je zdravilo Beromun v klinični uporabi namenjen za izolirano perfuzijo okončin v zdravljenju sarkoma mehkega tkiva.
No reproductive and developmental toxicity studies have been performed with ONIVYDE.
Študij škodljivih učinkov zdravila ONIVYDE na sposobnost razmnoževanja in razvoj niso izvedli.
No reproductive toxicity was observed in studies performed in rats and rabbits.
Študije na podganah in zajcih ne kažejo toksičnega vpliva na sposobnost razmnoževanja.
No response
brez odziva
No response at No Negative treatment sustained predictive week response value
Ni odziva Ni Negativna v tednu trajnega napovedna zdravljenja odziva vrednost
No response by week 12
Ni odziva do 12. tedna
No safety data are available to demonstrate the impact of vaccination on lactation.
Ni podatkov o varnosti, ki bi dokazovali vpliv cepljenja na laktacijo.
No safety data are available to demonstrate the impact of vaccination on lactation.
Ni podatkov o vplivu cepljenja na laktacijo.
No safety signals have been identified in this group.
V tej skupini niso zasledili nobenih varnostnih signalov.
No second or higher degree AV Block was seen in these studies.
Atrioventrikularni blok druge ali višje stopnje se v teh študijah ni pojavil.
No second or higher degree AV Block was seen in. these studies.
Atrioventrikularni blok druge ali višje stopnje se v teh študijah ni pojavil.
No second or higher degree AV Block was seen in.these studies.
Atrioventrikularni blok druge ali višje stopnje se v teh študijah ni pojavil.
No serious adverse reactions related to Amyvid administration have been reported.
Poročali niso o nobenih resnih neželenih učinkih, povezanih z uporabo zdravila Amyvid.
No serious adverse reactions related to DaTSCAN administration have been reported.
Ni poročil o resnih neželenih reakcijah, vezanih na uporabo zdravila DaTSCAN.
No serious IRRs were observed.
Resnih neželenih reakcij, povezanih z infuzijo, niso opazili.
No serious ophthalmic or systemic adverse reactions related to OPATANOL were reported in clinical studies.
V kliničnih študijah niso poročali o nobenih resnih očesnih ali sistemskih neželenih učinkih v povezavi z zdravilom OPATANOL.
No serious problems are expected with accidental overdose.
Pri naključnem prevelikem odmerjanju ni pričakovati resnih težav.
No side effects are known.
Neželeni učinki niso znani.
No side effects have been reported in association with this observation.
V povezavi s tem pojavom niso poročali o neželenih učinkih.
No significant changes in rufinamide concentration are observed following co-administration with lamotrigine, topiramate or benzodiazepines.
Po sočasni uporabi lamotrigina, topiramata ali benzodiazepinov ni opaziti značilnih sprememb koncentracije rufinamida.
No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite are observed with repeated daily administration or with repeated cycles in the dosing schedules tested.
Med ponavljajočo se vsakodnevno uporabo in med ponavljanjem ciklusov z uporabo testiranih odmernih shem niso opazili pomembnih sprememb v farmakokinetiki sunitiniba ali njegovega primarnega aktivnega presnovka.
No significant difference in OS was observed between the two treatment arms at the final OS analysis performed after 76% (280/369) of the events had occurred (HR 0.87, 95% CI 0.67, 1.12 p=0.256).
Celokupno preživetje se po končni analizi, opravljeni potem, ko se je pojavilo 76 % (280/369) dogodkov (razmerje ogroženosti 0,87, 95 % IZ 0,67, 1,12, p = 0,256), med terapevtskima krakoma ni značilno razlikovalo.
No significant difference was seen in the STEMI population.
V STEMI populacijah niso opazili značilne razlike.
No significant differences in Cmax and AUCτ were observed between healthy elderly females (≥ 65 years) and healthy young females (18-45 years).
Med zdravimi starejšimi ženskami (≥ 65 let) in zdravimi mladimi ženskami (18– 45 let) niso ugotovili pomembnih razlik v C max in AUCτ.
No significant differences in Cmax and AUCτ were observed between healthy elderly females (≥ 65 years) and healthy young females (18-45 years).
Med zdravimi starejšimi ženskami (≥ 65 let) in zdravimi mladimi ženskami (18–45 let) niso ugotovili pomembnih razlik v Cmax in AUCτ.
No significant differences in Cmax and AUCτ were observed between healthy elderly females (≥65 years) and healthy young females (18-45 years).
Med zdravimi starejšimi ženskami (≥ 65 let) in zdravimi mladimi ženskami (18–45 let) niso ugotovili pomembnih razlik v Cmax in AUCτ.
No significant differences in safety and efficacy of Perjeta were observed between elderly patients aged 65 to 75 years and adult patients aged < 65 years.
Med odraslimi bolniki, starimi med 65 in 75 let, ter odraslimi bolniki, mlajšimi od 65 let, niso ugotovili pomembnih razlik v varnosti in učinkovitosti zdravila Perjeta.
No significant differences were found in the efficacy and safety profiles of elderly patients and younger patients.
V profilih učinkovitosti in varnosti pri starejših in mlajših bolnikih ni bilo zaznati bistvenih razlik.
No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.
Med skupino, ki je jemala desloratadin, in tisto, ki je jemala placebo, niso ugotavljali statistično značilnih razlik v rezultatih testov psihofizične sposobnosti, ne glede na to ali so ga jemali samega ali sočasno z alkoholom.
No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.
Rezultati psihomotoričnega testiranja se med prejemniki desloratadina in placeba niso pomembno razlikovali, naj je bil uporabljen sam ali z alkoholom.
No significant effect of a single intravenous dose of tigecycline 50 mg or 200 mg on QTc interval was detected in a randomized, placebo- and active-controlled four-arm crossover thorough QTc study of 46 healthy subjects.
V randomizirani, s placebom in zdravilno učinkovino nadzorovani navzkrižni podrobni študiji QTc s štirimi skupinami, pri 46 zdravih preiskovancih niso ugotovili pomembnega učinka enkratnega intravenskega odmerka 50 mg ali 200 mg tigeciklina na interval QTc.
No significant effect on
Pomembnega vpliva na
No significant effect on
pomembnejših vplivov na
No significant effect on
Pomembnih učinkov na
No significant effect on atazanavir concentrations was observed.
Pomembnega vpliva na koncentracijo atazanavirja niso opazili.
No significant effect on darunavir/ritonavir PK parameters.
Brez pomembnega učinka na farmakokinetične parametre darunavirja/ritonavirja. tenofovir:
No significant effect on desipramine exposure was found.
Pomembnega učinka na izpostavljenost desipraminu niso našli.
No significant effect on lopinavir/ritonavir PK parameters.
Brez pomembnega učinka na farmakokinetične parametre lopinavirja/ritonavirja. tenofovir:
No significant effect on rosiglitazone exposure was found.
Pomembnega učinka na izpostavljenost rosiglitazonu niso našli.
No significant effect on the glucose level in healthy volunteers was observed.
Vrednost AUC se je povečala za 1,4-krat, pomembnega vpliva na koncentracijo glukoze pa niso zaznali.
No significant effects on the number of corpora lutea, implants, or live fetuses were observed.
Pomembnih učinkov na število rumenih telesc, nidacijo ali preživetje zarodkov niso opazili.
No significant effects were seen on vital organ systems, i.e. cardiovascular (dog), respiratory or central nervous systems (rat), after single dose administration of activities from 497 to 1100 kBq per kg body weight (9 [dog] to 20 [rat] times the clinically recommended activity).
Pomembnih učinkov na vitalne organske sisteme, tj. na kardiovaskularni sistem (pes), dihala ali osrednji živčni sistem (podgana) po enkratni uporabi odmerka z aktivnostjo od 497 do 1100 kBq na kg telesne mase (9-kratnik [psi] do 20-kratnik [podgane] klinično priporočene aktivnosti) niso opazili.
No significant impact of age (range: 28 years - 87 years) on the pharmacokinetics of afatinib could be observed.
Starost (razpon: 28-78 let) na farmakokinetiko afatiniba ni pomembneje vplivala.
No significant interactions have so far been noted, but caution should be exercised (see section 4.4).
Čeprav do zdaj pomembnejših medsebojnih učinkov niso zasledili, je potrebna previdnost (glejte poglavje 4.4).